Preventive sexual health screening among female-to-male (FTM) transgender adult patients

  • Principal Investigator(s): Sari Reisner
  • Study Contact: Dana Pardee, 617-927-6371, dpardee@fenwayhealth.org
  • Description of Subjects: Female-to-male (FTM) transgender individuals between the ages of 21-64 years who have a cervix and who have been sexually active in the past 36 months
  • Location (Domestic vs. International): Fenway Heatlh, Boston, MA
  • Enrollment Period: April 2015 - July 2016
  • Enrollment Goal: 150 participants
  • Key Exclusion and Inclusion Criteria: 1) Ages 21-64 years; 2) Assigned a female sex at birth and now self-identifiy as being on the FTM continuum; 3) Have a cervix; 4) Sexually active in the past 36 months
  • Available Biological Specimens: Other (None)
  • How to Request Access:Email study contact person directly
  • Available Data Description: HIV Rapid Test results; RPR, GC/CT (vaginal, rectal, pharyngeal), HPV results; Cervical Pap test results
  • Optional Additional Comments: The specific aims are as follows: Specific Aim 1: To quantitatively and qualitatively assess the acceptability, feasibility, and non-inferiority of vaginal self-swab for HPV DNA testing compared to provider cervical swab and Pap test results (cervical cytology) among sexually active FTMs. Specific Aim 2: To investigate the prevalence of other STIs among sexually active FTMs, concordance of self- and provider- swabs for STIs, and descriptively examine risk and protective factors for STI diagnosis.